- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07936357
Mindfulness Program for Blood Sugar Control, Heart Rate Variability, Anxiety, and Depression in Type 2 Diabetes
Effect of a Six-Week Mindfulness-Based Intervention on Glycemic Control, Cardiovascular Autonomic Function, Anxiety, and Depression in Adults With Type 2 Diabetes: A Randomized Controlled Trial
The goal of this clinical trial was to learn whether a six-week mindfulness program, added to standard diabetes treatment, improves blood sugar control, heart rate variability (a measure of how the nervous system regulates the heart), anxiety, and depression in adults aged 18 to 60 years with type 2 diabetes. The main questions it aimed to answer were:
- Does the mindfulness program lower glycated hemoglobin (HbA1c), fasting blood glucose, and 2-hour postprandial blood glucose?
- Does it improve heart rate variability, cardiovascular autonomic dysfunction status, and anxiety and depression scores?
Researchers compared participants who received standard therapy plus the mindfulness program with participants who received standard therapy alone.
Participants in the mindfulness group listened to weekly audio-guided practices sent through WhatsApp (mindful eating, breathing exercise, body scan, mindful walking, dealing with unpleasant experiences, and loving-kindness meditation) and were asked to practice daily for six weeks. All participants had blood tests, a 3-minute heart rate variability recording, and the Hospital Anxiety and Depression Scale questionnaire at the start of the study and after six weeks.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This single-center, parallel-group randomized controlled trial with a pretest-posttest design was conducted at the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, Indonesia, from March to June 2025. Adults with type 2 diabetes receiving antidiabetic treatment were randomly allocated in a 1:1 ratio to standard therapy plus a six-week mindfulness program (intervention) or standard therapy alone (control).
The mindfulness program was adapted from a mindfulness-based stress reduction (MBSR) handbook and consisted of one theme per week: mindful eating, breathing exercise, body scan, staying present (mindful walking), dealing with unpleasant experiences, and loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants were asked to practice daily (approximately 20 minutes per day) and received regular reminders.
Outcomes were assessed at baseline and after six weeks. HbA1c was measured with a point-of-care analyzer (Afinion HbA1c, Abbott); fasting and 2-hour postprandial venous blood glucose were measured with an enzymatic photometric method in the hospital laboratory. Short-term heart rate variability was recorded for 3 minutes with a fingertip photoplethysmographic sensor (SA-3000P, Medicore), and cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. Anxiety and depression were assessed with the Indonesian version of the Hospital Anxiety and Depression Scale.
The sample size (13 per group, increased to 14 per group to allow for 10% attrition; 28 in total) was calculated with OpenEpi (two-sided alpha 0.05, power 80%). Between-group comparisons used the independent t-test or Mann-Whitney U test, within-group comparisons used the paired t-test or Wilcoxon signed-rank test, and changes in autonomic dysfunction status were analyzed with the McNemar test.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Central Java
-
Surakarta, Central Java, Indonesien, 57126
- Dr. Moewardi General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults aged 18-60 years with type 2 diabetes mellitus
- Receiving antidiabetic treatment
- Attending the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital
- Willing to participate and provided written informed consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Thyroid disorders
- Cardiac arrhythmia
- Use of drugs that may affect heart rate variability (e.g., beta-blockers, antidepressants, antipsychotics, or anxiolytics)
- Coffee consumption within 1 week before the start of the study
- Anemia (hemoglobin <13 g/dL in men or <12 g/dL in women)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Mindfulness plus standard therapy
Participants continued their standard antidiabetic therapy and completed a six-week audio-guided mindfulness program delivered through WhatsApp. |
A six-week mindfulness program adapted from a mindfulness-based stress reduction (MBSR) handbook, with one theme per week: (1) mindful eating, (2) breathing exercise, (3) body scan, (4) staying present - mindful walking, (5) dealing with unpleasant experiences, and (6) loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants practiced daily (approximately 20 minutes per day) and received regular reminders, in addition to standard antidiabetic therapy.
Andre navne:
|
|
Ingen indgriben: Standard therapy
Participants continued their standard antidiabetic therapy without the mindfulness program. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in glycated hemoglobin (HbA1c)
Tidsramme: Baseline and 6 weeks
|
HbA1c (%) measured with a point-of-care analyzer (Afinion HbA1c, Abbott). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in fasting blood glucose
Tidsramme: Baseline and 6 weeks
|
Venous blood glucose after an 8-10-hour fast, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in 2-hour postprandial blood glucose
Tidsramme: Baseline and 6 weeks
|
Venous blood glucose 2 hours after a meal, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in standard deviation of normal-to-normal intervals (SDNN)
Tidsramme: Baseline and 6 weeks
|
Short-term heart rate variability (ms) from a 3-minute recording with a fingertip photoplethysmographic sensor (SA-3000P, Medicore). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Number of participants with cardiovascular autonomic dysfunction
Tidsramme: Baseline and 6 weeks
|
Cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) score
Tidsramme: Baseline and 6 weeks
|
HADS anxiety subscale, range 0-21; higher scores indicate more severe anxiety symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) score
Tidsramme: Baseline and 6 weeks
|
HADS depression subscale, range 0-21; higher scores indicate more severe depressive symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Farha Naily Fawzia, MD, Universitas Sebelas Maret
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Sygdomme i nervesystemet
- Psykiske lidelser
- Neuromuskulære sygdomme
- Metaboliske sygdomme
- Adfærdsmæssige symptomer
- Sygdomme i det perifere nervesystem
- Glukosemetabolismeforstyrrelser
- Diabetes mellitus
- Diabetes komplikationer
- Opførsel
- Ernæringsmæssige og metaboliske sygdomme
- Angstlidelser
- Diabetes mellitus, type 2
- Depression
- Diabetiske neuropatier
Andre undersøgelses-id-numre
- 2.765/XII/HREC/2024
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be made publicly available to protect participant privacy; de-identified data may be obtained from the principal investigator upon reasonable request.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .